Physician profile
Gabriel Lopez
NPI 1679077796
$1,082.64
in general payments reported to CMS, 2019-2025
11 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.99 · 2022: $50.94 · 2023: $108 · 2024: $352 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.17 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.06 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $120.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $117.66 | 2025 | Camzyos |
| Exact Sciences Corporation | $103.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $96.37 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $63.21 | 2024-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $24.72 | 2025 | Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2021 | |
| Phadia US INC. | $17.10 | 2024 | Immunocap |
| Glaxosmithkline, LLC. | $13.79 | 2025 | Arexvy, Shingrix |
| Vertos Medical, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.